PAR 2.63% 19.5¢ paradigm biopharmaceuticals limited..

Pfizer's Tanezumab receives almost unanimous rejection by FDA Adcom, page-17

  1. 145 Posts.
    lightbulb Created with Sketch. 27
    Ahhh, I see. Thanks for the clarification.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.